CeriBell (CBLL) Competitors $12.46 +0.48 (+4.01%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$12.24 -0.22 (-1.73%) As of 10/14/2025 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CBLL vs. ENOV, NVCR, CDRE, CNMD, SSII, PLSE, KMTS, BLFS, ESTA, and MDXGShould you be buying CeriBell stock or one of its competitors? The main competitors of CeriBell include Enovis (ENOV), NovoCure (NVCR), Cadre (CDRE), CONMED (CNMD), SS Innovations International (SSII), Pulse Biosciences (PLSE), Kestra Medical Technologies (KMTS), BioLife Solutions (BLFS), Establishment Labs (ESTA), and MiMedx Group (MDXG). These companies are all part of the "medical equipment" industry. CeriBell vs. Its Competitors Enovis NovoCure Cadre CONMED SS Innovations International Pulse Biosciences Kestra Medical Technologies BioLife Solutions Establishment Labs MiMedx Group CeriBell (NASDAQ:CBLL) and Enovis (NYSE:ENOV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership. Do insiders & institutionals have more ownership in CBLL or ENOV? 98.5% of Enovis shares are owned by institutional investors. 20.1% of CeriBell shares are owned by company insiders. Comparatively, 2.7% of Enovis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has preferable valuation & earnings, CBLL or ENOV? CeriBell has higher earnings, but lower revenue than Enovis. CeriBell is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCeriBell$65.44M6.98-$40.46M-$2.99-4.17Enovis$2.11B0.84-$825.49M-$14.25-2.18 Do analysts prefer CBLL or ENOV? CeriBell currently has a consensus price target of $32.14, suggesting a potential upside of 157.97%. Enovis has a consensus price target of $51.00, suggesting a potential upside of 64.22%. Given CeriBell's stronger consensus rating and higher probable upside, equities research analysts plainly believe CeriBell is more favorable than Enovis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CeriBell 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78Enovis 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Is CBLL or ENOV more profitable? Enovis has a net margin of -37.80% compared to CeriBell's net margin of -63.83%. Enovis' return on equity of 6.78% beat CeriBell's return on equity.Company Net Margins Return on Equity Return on Assets CeriBell-63.83% -48.42% -28.50% Enovis -37.80%6.78%3.73% Does the media prefer CBLL or ENOV? In the previous week, Enovis had 6 more articles in the media than CeriBell. MarketBeat recorded 10 mentions for Enovis and 4 mentions for CeriBell. Enovis' average media sentiment score of 0.78 beat CeriBell's score of 0.62 indicating that Enovis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enovis 3 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryEnovis beats CeriBell on 8 of the 15 factors compared between the two stocks. Get CeriBell News Delivered to You Automatically Sign up to receive the latest news and ratings for CBLL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CBLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CBLL vs. The Competition Export to ExcelMetricCeriBellMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$439.23M$10.60B$6.05B$10.52BDividend YieldN/A1.89%5.73%4.79%P/E Ratio-4.1720.9785.0427.24Price / Sales6.9836.83588.28231.77Price / CashN/A25.0637.5761.53Price / Book2.333.4412.676.74Net Income-$40.46M$210.63M$3.32B$276.59M7 Day Performance1.80%-2.33%-1.35%-0.47%1 Month Performance4.27%1.36%8.09%7.47%1 Year PerformanceN/A-6.13%78.89%34.58% CeriBell Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CBLLCeriBell2.2384 of 5 stars$12.46+4.0%$32.14+158.0%N/A$439.23M$65.44M-4.17N/AENOVEnovis3.6574 of 5 stars$31.30-2.2%$51.00+62.9%-22.5%$1.83B$2.11B-2.207,367Positive NewsNVCRNovoCure4.1111 of 5 stars$14.50-1.1%$27.50+89.7%-18.0%$1.64B$630.16M-9.291,488CDRECadre2.5272 of 5 stars$37.54+2.4%$31.50-16.1%+6.8%$1.49B$567.56M39.932,284CNMDCONMED4.5589 of 5 stars$46.42-3.6%$59.80+28.8%-30.9%$1.49B$1.31B13.153,900SSIISS Innovations InternationalN/A$6.80-5.4%N/AN/A$1.39B$20.65M0.004Gap UpPLSEPulse Biosciences3.7831 of 5 stars$19.45+0.8%$22.00+13.1%+4.5%$1.30B$700K-18.52140KMTSKestra Medical Technologies1.3597 of 5 stars$25.03+0.8%$27.33+9.2%N/A$1.28B$59.81M0.00300Gap UpBLFSBioLife Solutions1.9685 of 5 stars$26.52-0.3%$31.29+18.0%+18.0%$1.27B$82.25M-220.98440Gap DownESTAEstablishment Labs2.5599 of 5 stars$39.33-5.1%$56.50+43.7%+7.6%$1.20B$166.02M-12.901,018News CoverageMDXGMiMedx Group3.4319 of 5 stars$7.31+1.4%$12.00+64.2%+14.8%$1.07B$348.88M34.81870High Trading Volume Related Companies and Tools Related Companies Enovis Alternatives NovoCure Alternatives Cadre Alternatives CONMED Alternatives SS Innovations International Alternatives Pulse Biosciences Alternatives Kestra Medical Technologies Alternatives BioLife Solutions Alternatives Establishment Labs Alternatives MiMedx Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CBLL) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CeriBell, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CeriBell With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
